Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies.

Jaewon J Lee, Vincent Bernard, Alexander Semaan, Maria E Monberg, Jonathan Huang, Bret M Stephens, Daniel Lin, Kimal I Rajapakshe, Brian R Weston, Manoop S Bhutani, Cara L Haymaker, Chantale Bernatchez, Cullen M Taniguchi, Anirban Maitra, Paola A Guerrero

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 2022;27(21):5912-5921

PMID: 34426439

Abstract

PURPOSE

Precision medicine approaches in pancreatic ductal adenocarcinoma (PDAC) are imperative for improving disease outcomes. With molecular subtypes of PDAC gaining relevance in the context of therapeutic stratification, the ability to characterize heterogeneity of cancer-specific gene expression patterns is of great interest. In addition, understanding patterns of immune evasion within PDAC is of importance as novel immunotherapeutic strategies are developed.

EXPERIMENTAL DESIGN

Single-cell RNA sequencing (scRNA-seq) is readily applicable to limited biopsies from human primary and metastatic PDAC and identifies most cancers as being an admixture of previously described epithelial transcriptomic subtypes.

RESULTS

Integrative analyses of our data provide an in-depth characterization of the heterogeneity within the tumor microenvironment, including cancer-associated fibroblast subclasses, and predicts for a multitude of ligand-receptor interactions, revealing potential targets for immunotherapy approaches.

CONCLUSIONS

Our analysis demonstrates that the use of biopsies from patients with PDAC paired with scRNA-seq may facilitate therapeutic prediction from limited biopsy samples.

©2021 American Association for Cancer Research.

Address: Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas. [email protected] [email protected].; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.